AstraZeneca PLCAZN:LSE

4,067
17.00 / 0.42%
90.88k
9.21 %
0.6114
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Aug 28 2015 08:23 BST.

About the company

16.62bn766.28m199257.50k
Revenue in GBP (TTM)Net income in GBPIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
AstraZeneca PLC
- Legal Department, 2 Kingdom Street
LONDONW2 6BD
United Kingdom
GBR
Phone+44 20 7304 5000Fax+44 20 7604 8151Websitehttp://www.astrazeneca.com/
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company's pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

Mergers & acquisitions

There are no recent mergers or acquisitions for AstraZeneca PLC.
Data delayed at least 15 minutes, as of Aug 28 2015 08:23 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Shire PLC
4.04bn2.00bn29.80bn5.02k14.865.1113.017.383.393.556.829.860.43841.475.78805,16121.7025.5228.1925.5285.5885.8449.5129.930.443690.170.20187.3422.0514.90131.2545.47-21.686415.05
AstraZeneca plc
16.62bn766.28m51.81bn57.50k67.714.3617.283.120.60550.605513.159.390.45012.353.55288,9962.0814.462.9114.4679.5880.644.6119.170.71914.790.375664.411.49-4.473-51.7606-30.347411.654.01
GlaxoSmithKline plc
23.34bn9.67bn64.77bn98.70k6.649.506.152.772.012.014.821.400.50221.674.53236,49020.5714.9430.6214.9468.1671.2340.9715.480.96547.740.619393.67-13.2013-4.1036-49.301-13.0048-1.3385.57
Sanofi SA
26.57bn3.54bn84.85bn113.50k24.332.0415.483.193.643.6427.5243.350.38581.674.88320,6195.405.576.465.5768.0468.9614.0013.150.912116.440.20673.022.411.7818.14-3.5698-3.13713.50
Novo Nordisk A/S
9.69bn3.06bn74.64bn39.66k30.9324.5422.027.7011.9711.9737.9115.081.371.297.702,419,44043.1047.6975.6147.6984.7082.3131.5327.710.89439.860.018545.826.2611.705.1519.727.1827.23
Data as of Aug 28 2015. Currency figures normalised to AstraZeneca PLC's reporting currency: .
Data delayed at least 20 minutes, as of Aug 28 2015 08:09 BST.

Institutional shareholders

HolderShares% Held
BlackRock Investment Management (UK) Ltd.
as of 31 Jan 2015
65.63m5.19%
Legal & General Investment Management Ltd.
as of 01 Jul 2015
37.96m3.00%
Wellington Management Co. LLP
as of 01 Jul 2015
36.65m2.90%
The Vanguard Group, Inc.
as of 01 Jul 2015
26.17m2.07%
Invesco Asset Management Ltd.
as of 01 Jul 2015
23.62m1.87%
Norges Bank Investment Management
as of 01 Jul 2015
23.41m1.85%
Threadneedle Asset Management Ltd.
as of 01 Jul 2015
19.31m1.53%
Grantham, Mayo, Van Otterloo & Co. LLC
as of 01 Jul 2015
19.31m1.53%
Schroder Investment Management Ltd.
as of 01 Jul 2015
18.36m1.45%
Woodford Investment Management LLP
as of 01 Jul 2015
17.83m1.41%
22.81%
Per cent of shares
held by top holders
Data from 31 Dec 2014 - 20 Aug 2015Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.